Medical Lab Report Analysis - Omkar Nishad, 17 yr/M

Disclaimer: This is an educational analysis to help understand the reports. It is NOT a substitute for evaluation by a qualified physician. The reports themselves advise clinical correlation.

Report 1: Urine Routine & Microscopy - Key Findings

• Hematuria (blood in urine) - confirmed by both dipstick (+++) and microscopy (10-20 RBCs/HPF). This is significant hematuria.
• Bilirubinuria - bilirubin in urine is always abnormal and indicates either liver cell damage (hepatocellular disease) or bile duct obstruction. However, urobilinogen is normal, which suggests the bilirubin reaching the urine is conjugated (direct) bilirubin - pointing toward hepatocellular or cholestatic disease.
• No evidence of urinary tract infection (nitrite negative, leucocyte esterase negative, bacteria absent).

Report 2: USG Whole Abdomen - Key Findings

Synthesis & Differential Diagnosis

1. Splenomegaly
2. Minimal ascites
3. Bowel inflammation / increased bowel motility
4. Bilirubinuria (conjugated bilirubin leaking into urine)
5. Significant hematuria (10-20 RBCs/HPF)
6. GB sludge

Most Likely Diagnosis: Enteric Fever (Typhoid Fever)

• Splenomegaly is a classic and well-documented feature of typhoid fever, occurring in the majority of hospitalized cases. Per Harrison's Principles of Internal Medicine and the AAP Red Book: "Enteric fever is a syndrome characterized by fever, headache, abdominal pain, splenomegaly, and leukopenia."
• Bowel inflammation with increased peristalsis matches the intestinal phase of typhoid (Peyer patch involvement).
• GB sludge is consistent with Salmonella tropism for the gallbladder (S. Typhi colonizes the biliary system).
• Bilirubinuria can occur in typhoid due to mild hepatitis (typhoid hepatitis), causing conjugated bilirubin to spill into urine.
• Minimal ascites can accompany typhoid fever, particularly with enteric involvement.
• Hematuria, though less common, is a recognized complication - GI bleeding occurs in ~10% of hospitalized typhoid patients, and urinary involvement has been reported.

Secondary/Alternative Differentials to Exclude:

What Tests Should Be Done Next

1. Typhidot / Widal Test - rapid serology for Salmonella Typhi antibodies
2. Blood Culture - gold standard for typhoid (positive in ~60-80% in first week)
3. Complete Blood Count (CBC) - look for leukopenia (low WBC), relative lymphocytosis, thrombocytopenia (classic in typhoid)
4. Liver Function Tests (LFTs) - confirm/quantify hepatic involvement, measure direct vs. indirect bilirubin
5. Peripheral Blood Smear + Malaria RDT/PCR - to rule out malaria
6. Stool Culture - supportive evidence for enteric fever
7. Dengue NS1/IgM - Gorakhpur has high dengue burden; can cause thrombocytopenia + splenomegaly

Summary

Working Diagnosis: Enteric Fever (Typhoid/Paratyphoid Fever) with hepatic involvement

Histopathology Report Analysis - Mithu Devi, 40 yr / Female

Important Notice: This is a confirmed malignancy (cancer). The histopathology report has been issued and signed by two qualified MD Pathologists. The patient must be referred urgently to a gynecologic oncologist for staging and treatment planning without delay.

Patient & Specimen Details

What the Report Found

Specimen A - Cervical Biopsy (Microscopic Findings)

• Sheets of malignant squamous epithelial cells diffusely invading the cervical stroma
• Cells are moderately differentiated with moderate anisocytosis (variation in cell size) and anisonucleosis (variation in nuclear size)
• Hyperchromasia (dark-staining nuclei) with opened chromatin and prominent nucleoli - hallmark features of malignant cells
• Mixed cytoplasm: some cells clear, some eosinophilic (indicating squamous lineage)
• Stroma infiltrated by chronic inflammatory cells

Specimen B - Endometrial Biopsy (Microscopic Findings)

• No normal endometrial tissue is seen
• The section shows infiltration by the same tumor described in specimen A
• This means the cervical cancer has extended into the uterine cavity/endometrium

Pathologist's Final Opinion (as stated in report)

Clinical Interpretation

Diagnosis: Invasive Squamous Cell Carcinoma of the Cervix with Uterine/Endometrial Extension

• Large polygonal cells forming sheets and nests
• No keratin pearl formation (unlike well-differentiated keratinizing type)
• Greater nuclear pleomorphism - more aggressive than well-differentiated but better than small cell type

Urgent Next Steps Required

1. MRI Pelvis with contrast - to assess: parametrial invasion, depth of stromal invasion, vaginal involvement, lymph node status. MRI is the gold standard for local staging of cervical cancer.
2. CT Chest/Abdomen/Pelvis (or PET-CT) - to detect distant lymph node metastases (iliac, para-aortic) and distant spread (lungs, liver, bones).
3. Complete gynecologic examination under anesthesia (EUA) - clinical staging by gynecologic oncologist.
4. HPV genotyping - not mandatory for treatment but prognostically informative.
5. Hemoglobin / CBC / Renal function tests - pre-treatment baseline, especially important before radiation therapy (anemia worsens radiation response).
6. Urgent referral to Gynecologic Oncology - treatment options include surgery (radical hysterectomy for early stage) or chemoradiation (cisplatin-based concurrent chemoradiotherapy is standard for locally advanced disease).

5-Year Survival Reference (by FIGO Stage)

Summary

Diagnosis: Invasive Squamous Cell Carcinoma of the Cervix (Moderately Differentiated, Large Cell Non-Keratinizing), with Extension to Endometrium

Treatment Plan: Cervical Squamous Cell Carcinoma with Uterine Extension

Patient: Mithu Devi, 40 yrs / Female

Note: Treatment must be planned by a gynecologic oncologist after formal FIGO staging via MRI and CT/PET-CT. This guide presents the evidence-based framework from current international guidelines (FIGO 2018, ESGO 2023, NCCN, Berek & Novak's Gynecology).

Step 1: Staging First (Determines Everything)

Stage-Based Treatment Algorithm

If Stage IIA (cervix + upper vagina, no parametrial involvement)

• Type III Radical Hysterectomy (Wertheim's hysterectomy) + bilateral pelvic lymph node dissection
• Removes: uterus, cervix, upper 1/3 vagina, parametrium, pelvic lymph nodes
• At age 40, ovaries can be preserved (squamous cell carcinoma rarely spreads to ovaries - <1% risk)
• If post-operative pathology shows high-risk features (positive nodes, positive margins, parametrial invasion) → add adjuvant chemoradiation
• 4-year survival with adjuvant chemoradiation after surgery: ~81% (GOG intergroup trial)

• Used if tumor >4 cm, patient unfit for surgery, or if surgery would require adjuvant radiation anyway (avoids dual-modality morbidity)

If Stage IIB or III (parametrial invasion / pelvic wall involvement) - Likely in this case

Standard Treatment: Concurrent Chemoradiation (CCRT) + Brachytherapy

• Whole pelvis radiation: 45-50 Gy delivered in 25-28 fractions over 5 weeks
• Covers the cervix, uterus, parametrium, regional lymph nodes
• Must be completed within 8 weeks total

• Cisplatin 40 mg/m² IV weekly during radiation (5-6 cycles)
• Cisplatin sensitizes cancer cells to radiation, improving local control and survival
• Survival benefit over radiation alone: 10-15% at 5 years (meta-analysis of 18 RCTs)
• Per Berek & Novak's Gynecology: "Cisplatin-based concurrent chemoradiation was a superior treatment" - established by GOG protocols 85, 120

• After EBRT, high-dose rate (HDR) intracavitary brachytherapy is given
• Delivers high-dose radiation directly to the cervix/uterus
• 3-5 fractions of 6-7 Gy each
• This is what achieves local tumor control - EBRT alone is insufficient
• Total treatment must be completed within 8 weeks (longer duration = worse outcomes)

2024-2025 Update: Immunotherapy Addition (Pembrolizumab)

• Adding pembrolizumab (Keytruda) to standard CCRT for high-risk locally advanced cervical cancer (Stage IIB+ with nodes, or Stage III-IVA) showed:
  • Improved progression-free survival (HR 0.70, p=0.002)
  • 24-month overall survival: 87% vs 81% over CCRT alone
• FDA approved pembrolizumab + CCRT for FIGO Stage III-IVA cervical cancer in January 2024
• This combination is now considered the emerging standard of care for advanced disease

Full Treatment Timeline (Typical Course)

Week 1-6:   External Beam Radiotherapy (45-50 Gy / 25 fractions)
             + Weekly Cisplatin (40 mg/m² IV) × 5-6 doses
             [+ Pembrolizumab if Stage IIB+ and available]

Week 7-8:   Brachytherapy (HDR) × 3-5 sessions
             [Total treatment ≤ 8 weeks]

After CCRT: Follow-up every 3 months × 2 years, then 6-monthly
             MRI pelvis at 3 months post-treatment to assess response

Managing Side Effects

Prognosis with Treatment

What to Do Right Now

1. Go to a Cancer Centre / Gynecologic Oncology department immediately - ideally a government cancer hospital (RIMS Lucknow, BHU Varanasi, SGPGI Lucknow, Tata Memorial Mumbai) which offers subsidized/free treatment under Ayushman Bharat (PMJAY) scheme
2. Take this histopathology report along with the slides and tissue blocks (the report says "enclosed slides & blocks for second opinion if required")
3. Get an MRI pelvis with contrast before the first oncology appointment
4. Do not delay - this tumor is already beyond the cervix; every week matters